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Hypercalcemic Disorders in Children
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1Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
2Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
3Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Oxford, UK
ABSTRACT
Hypercalcemia is deﬁned as a serum calcium concentration that is greater than two standard deviations above the normal
mean, which in children may vary with age and sex, reﬂecting changes in the normal physiology at each developmental stage.
Hypercalcemic disorders in children may present with hypotonia, poor feeding, vomiting, constipation, abdominal pain,
lethargy, polyuria, dehydration, failure to thrive, and seizures. In severe cases renal failure, pancreatitis and reduced
consciousness may also occur and older children and adolescents may present with psychiatric symptoms. The causes of
hypercalcemia in children can be classiﬁed as parathyroid hormone (PTH)-dependent or PTH-independent, and may be
congenital or acquired. PTH-independent hypercalcemia, ie, hypercalcemia associated with a suppressed PTH, is commoner in
children than PTH-dependent hypercalcemia. Acquired causes of PTH-independent hypercalcemia in children include
hypervitaminosis; granulomatous disorders, and endocrinopathies. Congenital syndromes associated with PTH-independent
hypercalcemia include idiopathic infantile hypercalcemia (IIH), William’s syndrome, and inborn errors of metabolism. PTH-
dependent hypercalcemia is usually caused by parathyroid tumors, which may give rise to primary hyperparathyroidism
(PHPT) or tertiary hyperparathyroidism, which usually arises in association with chronic renal failure and in the treatment of
hypophosphatemic rickets. Acquired causes of PTH-dependent hypercalcemia in neonates include maternal hypocalcemia
and extracorporeal membrane oxygenation. PHPT usually occurs as an isolated nonsyndromic and nonhereditary
endocrinopathy, but may also occur as a hereditary hypercalcemic disorder such as familial hypocalciuric hypercalcemia,
neonatal severe primary hyperparathyroidism, and familial isolated primary hyperparathyroidism, and less commonly, as part
of inherited complex syndromic disorders such as multiple endocrine neoplasia (MEN). Advances in identifying the genetic
causes have resulted in increased understanding of the underlying biological pathways and improvements in diagnosis. The
management of symptomatic hypercalcemia includes interventions such as ﬂuids, antiresorptive medications, and
parathyroid surgery. This article presents a clinical, biochemical, and genetic approach to investigating the causes of
pediatric hypercalcemia. © 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
Hypercalcemia in children is less common than in adults, but itnevertheless is more likely to be of clinical signiﬁcance.(1)
The differential diagnosis of hypercalcemia in children (Table 1)
and adults is similar, but there are marked differences in the
frequencies with which they occur. Thus, congenital causes are
more frequent in children than acquired causes, such as
malignancy, which are more common in adults (Table 1).(1) The
causes of the hypercalcemia also depend on the age of the child,
with congenital anomalies beingmore common in neonates, and
with adolescents being affected by conditions typically seen in
adults. Establishing the causes of hypercalcemia in a childmay be
challenging; this article reviews these etiologies and proposes a
clinical algorithm to facilitate their diagnosis.
Definition and Presentation of Hypercalcemia
Hypercalcemia is deﬁned as a serum calcium concentration that is
greater than two standard deviations above the normal mean,
which in adults is usually an ionized calcium above1.32mmol/L
(normal range, 1.16 to 1.32mmol/L) (Table 2) and a total serum
calcium,which comprises 55% to 60% ionized calciumplus 40% to
45%protein-bound (mainly to albumin) calcium, of2.60mmol/L
(normal range, 2.20 to 2.60mmol/L, 8.5 to 10.5mg/dL). It is
important to distinguish true hypercalcemia from an increased
total calcium level secondary to an increase in protein binding
because the two conditions may also overlap. For example,
hypercalcemia can cause severe dehydration that in turn may
result in hyperalbuminemia, resulting in a concurrent increase in
calcium binding. The total calcium adjusted for albumin is
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calculated by the following formulas: adjusted calcium¼ total
calcium – albuminþ 4.0, where calcium is in mg/100mL and
albumin in g/100mL(2); or adjusted calcium¼ total calciumþ ({40
– albumin} 0.02), where calcium is inmmol/L and albumin in g/L
(equivalent to0.02mmol/L calcium for every1g/L albumin40g/L).
Moreover, ionized and total serum calcium concentrations may
varywith age and sex, reﬂecting changes in the normal physiology
at each developmental stage; reference ranges have been
established for the different age groups (Table 2). Generally,
ionized and total serum calcium concentrations are higher in
preterm and full-term neonates, where ionized calcium is above
the 95% reference limits for adults fromabout the thirdday until at
least 2 weeks postpartum.(3)
The presentation of hypercalcemia in children may range
from an incidental asymptomatic biochemical ﬁnding to
symptoms of hypotonia, poor feeding, vomiting, constipation,
Table 1. Causes of Hypercalcemia in Children
PTH-dependent hypercalcemia PTH-independent hypercalcemia
Genetic FHH1-3; nsPHPT; NSHPT; FIHP; MEN 1, 2, 3 and 4; HPT-JT IIH; Williams syndrome; Down syndrome; hypophosphatasia;
Jansen’s disease; inborn errors of metabolism (eg, CLD,
Bartter syndrome, blue diaper syndrome, sucrose-isomaltase
deficiency, primary oxalosis, IMAGe syndrome)
Acquired Tertiary hyperparathyroidism due to chronic renal failure
or treatment for hypophosphatemic rickets; gestational
maternal hypocalcemia
Hypervitaminosis D and A; malignancies causing osteolysis
(eg, ALL, AML), or secreting PTHrP (eg, lymphoma,
medulloblastoma, rhabdomyosarcoma, hepatoblastoma, or
hepatocellular carcinoma), or secreting 1,25(OH)2D3 (eg,
lymphoma or ovarian dysgerminoma); drugs (eg, thiazides),
chemotherapy including 13-cis-retinoic acid; milk-alkali
syndrome; granulomatous disease (eg, subcutaneous fat
necrosis of the newborn, tuberculosis, sarcoidosis, HIV
immune reconstitution syndrome, cat scratch fever,
histoplasmosis, coccidiomycosis, leprosy); endocrinopathies
(eg, thyrotoxicosis, congenital hypothyroidism, Addison’s
disease, pheochromocytoma); distal renal tubular acidosis.
Multicystic dysplastic kidney disease and renal dysplasia;
chronic inflammatory disorders (eg, Crohn’s disease);
infection (eg, disseminated CMV); immobilization; nutritional
and phosphate depletion in preterm neonates
Causes more likely to be contributing to neonatal or infantile hypercalcemia are shown in italics.
PHPT¼primary hyperparathyroidism; FHH1/FHH2/FHH3¼ familial hypocalciuric hypercalcemia types 1, 2, and 3; nsPHPT¼nonsyndromic primary
hyperparathyroidism; NSHPT¼neonatal severe primary hyperparathyroidism; FIHP¼ familial isolated hyperparathyroidism; MEN1/MEN2/MEN3/
MEN4¼multiple endocrine neoplasia types 1, 2, 3, and 4; HPT-JT¼hyperparathyroid jaw-tumor syndrome; IIH¼ idiopathic infantile hypercalcemia;
CLD¼ congenital lactase deﬁciency; IMAGe syndrome¼ syndrome characterized by intrauterine growth restriction, metaphyseal dysplasia, adrenal
hypoplasia congenita, and genital anomalies; ALL¼ acute lymphoblastic leukemia; AML¼ acute myeloid leukemia; 1,25(OH)2D3¼ 1,25-dihydrox-
yvitamin D3; HIV¼human immunodeﬁciency virus; CMV¼ cytomegalovirus.
Table 2. Age-Speciﬁc Reference Intervals for Serum Total and Ionized Calcium Concentrations
Total calciuma Ionized calciumb
Reference mg/dL mmol/L mg/dL mmol/L
Cord blood 8.2–11.2 2.05–2.80 5.20–6.40b 1.30–1.60b
Neonate (24 hours) NR NR 4.40–5.44b 1.10–1.36b
Neonate (5 days) NR NR 4.88–5.92b 1.22–1.38b
Birth to 90days 8.0–11.3a 2.00–2.80a NR NR
91–180 days 8.9–11.2a 2.20–2.80a NR NR
181–364 days 9.0–11.3a 2.30–2.80a NR NR
1–3 years 8.9–11.1a 2.20–2.80a 4.80–5.52b 1.20–1.38b
4–11 years 8.7–10.7a 2.20–2.70a 4.80–5.52b 1.20–1.38b
12–18 years 8.5–10.7a 2.10–2.70a 4.80–5.52b 1.20–1.38b
>19 years 8.5–10.5a 2.20–2.60a 4.64–5.28b 1.16–1.32b
NR¼not reported.
aSerum total calciummeasured in vitaminD–replete children and young adults, excluding those from renal, endocrine, and critical care unit; thus, these
individuals likely had a plasma albumin in the normal range (with serum 25(OH)D3 concentrations of 30 to 80mg/dL or 75 to 200 nmol/L) and adapted
from Roizen JD, Shah V, LevineMA, CarlowDC (Determination of reference intervals for serum total calcium in the vitamin D-replete pediatric population.
J Clin Endocrinol Metab. 2013;98(12):E1946–50).
bCord blood calcium concentrations and serum ionized calcium concentrations adapted fromAlanWu (Tietz Clinical Guide to Laboratory Tests. 4th ed.
Philadelphia: Saunders; 2006).
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abdominal pain, lethargy, failure to thrive, polyuria, dehydra-
tion, and seizures.(4,5) In severe cases, renal failure, pancreatitis,
and reduced consciousness may also occur, and older children
and adolescents may present with psychiatric symptoms.(6)
Clinical history and examination may provide diagnostic clues
and guide further investigations. The presence or absence of
symptoms of hypercalcemia may indicate a particular
diagnosis, and the urgency with which investigations should
be pursued. For example, mild, nonprogressive, asymptomatic
hypercalcemia may potentially indicate a diagnosis of familial
hypocalciuric hypercalcemia (FHH), whereas severe hypercal-
cemia associated with fractures and respiratory distress is
suggestive of the life-threatening disorder of neonatal severe
primary hyperparathyroidism (NSHPT).(7) In addition, a dietary
assessment, details of existing medical problems and medi-
cations (including over-the-counter supplements), and a
family history may help to reveal the cause of the
hypercalcemia. Physical examination should include an
assessment for dysmorphic features, which may reveal a
genetic syndrome, and for sequelae of hypercalcemia, such as
bony deformities. Finally, the clinical details of the parents
should be assessed because the neonate’s condition will have
been inﬂuenced by the in utero environment. In addition, it is
important to measure the serum calcium concentrations of the
parents, because a hypercalcemic neonate may have inherited
FHH from the mother, or be at a high risk of developing
transient NSHPT if inheritance of FHH, due to an inactivating
calcium-sensing receptor (CaSR) mutation, is from the father
and the mother is normocalcemic.(8)
Classification of Hypercalcemia and
Pathophysiology
There is no formal classiﬁcation or grading system for deﬁning
the severity of hypercalcemia. However, the severity of clinical
symptoms are more likely to be associated with greater
elevations in plasma calcium concentrations, and hypercalcemia
is generally considered to bemild,moderate, and severe for total
serum calcium concentrations <12mg/dL (3.00mmol/L), be-
tween 12 and 14mg/dL (3.00 to 3.50mmol/L), and >14mg/dL
(3.50mmol/L), respectively.(9) A classiﬁcation of hypercalcemia
that is useful in identifying the underlying etiologies can also be
based on an understanding of the pathophysiological mecha-
nisms. Thus, hypercalcemia may arise through increased bone
resorption (eg, from lytic bone lesions), increased gastrointesti-
nal absorption of calcium (eg, through enhanced 1,25(OH)2D3
production), and decreased renal excretion of calcium (eg,
through the action of thiazides) (Fig. 1). Hypercalcemia may
result frommore thanonemechanism; for example, excessive PTH
causes increased gut absorption of calcium through enhanced
1,25(OH)2D3 production, and also stimulates calcium resorption in
bone and and calcium reabsorption in the renal tubules. The
causes of hypercalcemia may also be classiﬁed by whether the
circulating PTH concentrations are elevated, ie, hypercalcemia
that is PTH-dependent (eg, as occurring in parathyroid tumors), or
reduced, ie, hypercalcemia that is PTH-independent (eg, through
excessive production of parathyroid hormone-related protein [or
PTHrP] by a cancer, or an excess production of downstream
mediators such as 1,25(OH)2D3) (Table 1, Fig. 2). Primary
hyperparathyroidism (PHPT) and malignancy, which account for
>90% of hypercalcemia in adults,(10) are rare in children and likely
account for <5% of hypercalcemia in children, in whom other
causes, especially those that are PTH-independent and due to
genetic abnormalities, are more likely (Table 1). A careful history
(eg, for vitamin D ingestion, drugs, renal disease) and examination
(eg, for dysmorphology, endocrinopathies, granulomatous dis-
eases), together with appropriate investigations will help to
establish the diagnosis.
PTH-Independent Hypercalcemia
PTH-independent hypercalcemia, which is commoner in
children than PTH-dependent hypercalcemia, may be due to
many and diverse causes that may be genetic or acquired
(Table 1) and include hypervitaminosis D and A, drugs,
malignancies, granulomatous disorders, endocrinopathies, renal
tubular disorders, chronic inﬂammatory disorders, infections,
immobilization, congenital syndromes, and inborn errors of
metabolism. These disorders, some of which may be associated
with either high plasma concentrations of 25(OH)D3 or 1,25
(OH)2D3 concentrations, are reviewed in the next sections
(Fig. 2).
Hypercalcemia associated with high plasma 25(OH)D3
concentrations
Hypercalcemia following vitamin D intoxication may occur due
to incorrect prescriptions or accidental overdosing.(11–14) For
Fig. 1. Hormonal regulation of extracellular calcium homeostasis. PTH is
the principal calciotropic hormone, and acts to elevate calcium levels by
promoting osteoclastic activity on bone, increasing reabsorption of
calcium from renal distal tubules and collecting ducts, and stimulating
renal enzyme 1a-hydroxylase conversion of 25(OH)D3 into the active
1,25(OH)2D3. 25(OH)D3 is produced from vitamin D3, formed by the
action of solar UVB on the skin or taken in through the diet, by the liver
enzyme 25-hydroxylase. 1,25(OH)2D3 is released into the circulation and
stimulates calcium uptake from the gut. Rising serum calcium levels are
detected by the CaSR, which facilitates a negative feedback on the
parathyroid glands and PTH secretion attenuates to maintain homeo-
stasis. 1,25(OH)2D3 is also regulated by FGF23, the main function of
which is to regulate plasma phosphate concentrations. It is secreted by
osteocytes in response to an elevated 1,25(OH)2D3 concentration and
acts on the kidney proximal tubules to inhibit reabsorption and increase
excretion of phosphate. It also inhibits 1a-hydroxylase, thereby exerting
a negative feedback on 1,25(OH)2D3 and promotes the action of 1,25
(OH)2D3 24-hydroxylase, leading to lower levels of 1,25(OH)2D3 and
reduced calcium absorption from the gut. 25(OH)D3¼ 25-hydroxyvita-
min D3; 1,25(OH)2D3¼ 1,25-dihydroxyvitamin D3; CaSR¼ calcium-sensing
receptor; FGF23¼ ﬁbroblast growth factor-23; PTH=parathyroid hormone.
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example, in the summer of 2016, >70 children were reported
to have developed hypercalcemia after receiving a vitamin D
preparation that contained 75 times higher levels than those
recommended.(15,16) Hypercalcemia may also complicate the
use of single high-dose vitamin D therapy (600,000 IU vitamin
D3, also known as Stoss [from the German “to shove”] therapy),
that is utilized by some centers for the treatment of vitamin D
insufﬁciency or deﬁciency in children with rickets or cystic
ﬁbrosis.(17–20) The precise mechanism by which high doses of
25(OH)D3 can cause hypercalcemia remains unclear. In normal
physiology, 25(OH)D3 binds to the vitamin D receptor (VDR)
with very low afﬁnity in contrast to its active metabolite, 1,25
(OH)2D3. In 25(OH)D3 toxicity, 25(OH)D3 precursors and
metabolites are elevated but 1,25(OH)2D3 is usually normal,
thereby suggesting that the hypercalcemia is not due to the
actions of 1,25(OH)2D3. It has been proposed that the high
concentrations of circulating 25(OH)D3 displace 1,25(OH)2D3
from the vitamin D binding protein, thereby increasing the
free concentrations of 1,25(OH)2D3, which then stimulate gene
transcription via the VDR.(21) It is important to note that
excessive exposure to sunlight does not pose a risk of vitamin
D toxicity because the UVB light stimulates production and
Fig. 2. Clinical approach to investigation of causes of hypercalcemia in a child. aConﬁrm hypercalcemia, deﬁned as plasma (or serum) adjusted calcium
> 10.5 mg/dL (2.60mmol/L) or ionized calcium> 5.25mg/dL (1.32mmol/L) (see Table 2). bPTH–parathyroid hormone. c25(OH)D–25-hydroxyvitamin D.
dFHH1-3– Familial Hypocalciuric Hypercalcemia types 1-3; MEN1–Multiple Endocrine Neoplasia type 1; MEN2–Multiple Endocrine Neoplasia type 2;
MEN3–Multiple Endocrine Neoplasia type 3; MEN4–Multiple Endocrine Neoplasia type 4; NSHPT–Neonatal Severe Primary Hyperparathyroidism; HPT-JT–
Hyperparathyroid-Jaw Tumour syndrome. eFamilial Isolated Hyperparathyroidism. fConditions affecting neonates (shown in italics). g1,25(OH)2D–1,25-
dihydroxyvitamin D. hInborn errors of metabolism, e.g. Hypophosphatasia, Congenital Lactase Deﬁciency (CLD) and blue diaper syndrome. iThese
syndromes may be associated with dysmorphic features, e.g. Williams syndrome, Jansen’s metaphyseal chondrodysplasia, Hypophosphatasia.
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destruction of vitamin D3. Thus, 7-dehydroxyxholesterol is
converted to previtamin D3 under UVB, and previtamin D3 is
then converted to vitamin D3 at the plasma membrane;
however, UVB light also degrades previtamin D3 and vitamin
D3, thereby allowing an equilibrium to be reached and thereby
preventing excessive vitamin D3 production.
(22)
Hypercalcemia associated with high plasma 1,25(OH)2D3
concentrations
High circulating 1,25(OH)2D3 concentrations may arise because
of excessive renal synthesis associated with phosphate deple-
tion, extrarenal activation of the 1a-hydroxylase enzyme with
overproduction of 1,25(OH)2D3, or because of impaired renal
catabolism of 1,25(OH)2D3 to its inactive metabolite 1,24,25
(OH)3D3 (Fig. 1).
Increased renal synthesis of 1,25(OH)2D3 in association with
phosphate depletion
Vitamin D metabolism is affected by phosphate homeostasis
and the actions of the phosphate hormone ﬁbroblast growth
factor-23 (FGF23), which are to inhibit and stimulate the
activities of the renal 1a-hydroxylase (CYP27B1) and 1,25-
dihydroxyvitamin D-24-hydroxylase (CYP24A1), respectively
(Fig. 1). Renal phosphate reabsorption in the proximal tubule
involves the sodium-phosphate cotransporters 2A (NaPi-IIa)
and 2C (NaPi-IIc), and phosphate reabsorption by NaPi-IIa is
controlled by FGF23 and PTH.(23) Loss of phosphate transport
activity due to defects of NaPi-IIa, encoded by the solute
carrier 34A1 gene (SLC34A1), results in phosphate depletion
with a decrease in circulating FGF23 concentrations, that
releases the inhibition of the 1a-hydroxylase and causes
inappropriate excessive production of 1,25(OH)2D3,
(23) which
leads to hypercalcemia, hypercalciuria, and nephrocalcinosis, a
combination of features seen in children with idiopathic
infantile hypercalcemia (IIH). IIH classically presents in the ﬁrst
year of life with failure to thrive, vomiting, dehydration, and
lethargy, and may be fatal. The hypercalcemia usually resolves
by 1 year of age, but in some individuals it may persist into
adulthood.(24) In addition, some patients may later develop
hypercalciuria and be at risk of developing renal stone disease
and osteoporosis, such that long-term surveillance is recom-
mended for these patients.(25) IIH is an autosomal recessive
disorder, and two types of IIH (IIH1 and IIH2) are recognized,
and are due to homozygous, or compound heterozygous
mutations of the CYP24A1 and SLC34A1 genes.(23,26,27)
Extrarenal synthesis of 1,25(OH)2D3 in malignant and granuloma-
tous diseases
Lymphomas and ovarian dysgerminomas can be extrarenal sites
of 1a-hydroxylase activity, and hypercalcemia due to elevated
production of 1,25(OH)2D3, and may occur in 15% and 5% of
patients with non-Hodgkin’s and Hodgkin’s lymphoma, respec-
tively.(28,29) Similarly, macrophages represent an extrarenal site
that can have substantial 1a-hydroxylase activity. Sequestration
ofmacrophages in granulomatous and inﬂammatory tissues (eg,
sarcoidosis, tuberculosis, human immunodeﬁciency virus [HIV]
immune reconstitution syndrome, leprosy, fungal granuloma
including coccidiomycosis, cat scratch fever, Crohn’s disease,
CMV, histoplasmosis, and subcutaneous fat necrosis of the
newborn) can cause dysregulated production of 1,25(OH)2D3,
leading to hypercalcemia.(30–36) Subcutaneous fat necrosis of the
newborn (SFN) is an unusual form of lobular panniculitis that
typically affects newborns born at term or postterm, often with a
preceding history of birth trauma or birth asphyxia, and may
occur from birth up until the ﬁrst 6 weeks of life. SFNmay also be
associated with hypothermia or therapeutic cooling, and is
characterized by single or multiple erythematous violaceous
plaques and nodules that can evolve into calciﬁcations and tend
to occur on the back, face, buttocks, and shoulders.(31,32) It is
associated with hypercalcemia that can be life-threatening and
the severity and duration of hypercalcemia are associated with
the extent of the skin lesions.(31) It has been proposed that an
insult on the immature fat cells, such as exposure to cold (eg,
therapeutic hypothermia for hypoxia-ischemia encephalopathy
or hypoperfusion),(31) may result in the development of necrosis
and the development of a granulomatous inﬁltrate in the
necrotic areas. In keeping with this, abundant levels of 1a-
hydroxylase have been found in affected tissues, whichmay lead
to increased production of 1,25(OH)2D3 with associated
hypercalcemia as reported in other granulomatous disorders.(37)
Impaired degradation of 1,25(OH)2D3
Loss-of-function mutations of 1,25-dihydroxyvitamin D3
24-hydroxylase, encoded by cytochrome P450 family 24
subfamily A member 1 (CYP24A1), resulting in impaired
catabolism of 25(OH)D3 and 1,25(OH)2D3 to their inactive
metabolites 1,24,25(OH)3D3 and 24,25(OH)2D3, may be
associated with elevated circulating levels of the active
metabolites and the disorder IIH.(25,38)
Hypercalcemia not associated with altered vitamin D
concentrations
PTH-independent hypercalcemia may arise without alterations
in circulating 25(OH)D3 or 1,25(OH)2D3 concentrations, and the
causes for this form of hypercalcemia include: malignancies that
may produce PTHrP; drugs and vitamins; endocrinopathies;
renal tubular disorders; congenital and hereditary syndromes
and skeletal diseases; inborn errors of metabolism; and speciﬁc
neonatal disorders.
Drugs and vitamin A toxicity
Drugs such as thiazides and vitamin A (retinol), vitamin A
derivatives (eg, its active metabolite, retinoic acid), and
inappropriate doses of calcium carbonate and sodium bicar-
bonate to patients with chronic renal failure resulting in milk
alkali syndrome can cause hypercalcemia.(39–44) Thus, thiazides
act to increase renal calcium reabsorption, which may cause
hypercalcemia or unmask hypercalcemia from other causes that
had been compensated for by hypercalciuria.(40,43,44) Isotreti-
noin (13-cis-retinoic acid), which is used for treatment of severe
acne and neuroblastoma, may also cause hypercalcemia by
increasing osteoclastic bone resorption.(41,45) However, vitamin
A toxicity is a rare cause of hypercalcemia and may occur in
children with malabsorptive conditions such as cystic ﬁbrosis(39)
given supplements containing preformed vitamin A, of which
70% to 90% is absorbed, thereby making children particularly
sensitive to overdose. It is important to note that vitamin A
toxicity does not occur with high intake of provitamin
carotenoids from fruit and vegetables because conversion to
the active form of vitamin A is required, and this rarely occurs
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when large quantities of foods such as ﬁsh or animal liver that
contain a bioavailable form (retinol) are ingested.
Malignancy and PTHrP
Cancers associated with hypercalcemia in children include
hematological malignancies (eg, leukemias, lymphomas, and
myeloma), neurological tumors including neuroblastoma,
rhabdomyosarcoma, hepatic tumors (eg, hepatoblastoma and
hepatocellular carcinoma), and dysgerminomas.(46–50) Hypercal-
cemia is associated with malignancy in <1% of children,(4) and
may be caused by: osteolysis due to metastases or leukemias; or
osteoclastic bone resorption stimulated by hormones (eg,
PTHrP) that are produced by the tumor. PTHrP acts as a
paracrine and intracrine hormone to regulate bone develop-
ment, but some tumors (eg, renal cell carcinomas, squamous cell
carcinomas, dysgerminomas, ovarian and breast carcinomas,
pheochromocytoma,(51,52) benign congenital mesoblastic neph-
roma,(53) multicystic dysplastic kidney disease,(54) and renal
dysplasia(55,56)) may secrete PTHrP systemically, and the actions
of circulating PTHrP on the type 1 PTH/PTHrP receptor cause
hypercalcemia.
Endocrinopathies
Endocrine disorders, such as pheochromocytoma, Addison’s
disease, thyrotoxicosis, and severe congenital hypothyroidism,
may be associated with development of hypercalcemia in
children. The hypercalcemia associated with pheochromocy-
toma may be due to secretion of PTHrP.(51,52) In Addison’s
disease the hypercalcemia may be due to increased intestinal
calcium absorption,(57) that is possibly aggravated by volume
depletion due to lack of mineralocorticoid hormone. Thyroid
hormone in children increases bone resorption and skeletal
growth; however, in thyrotoxicosis there is also premature
fusion of growth plates, resulting in short stature,(57) which leads
to a negative balance between bone formation and resorp-
tion,(58) and this may possibly explain the development of
hypercalcemia. Severe congenital hypothyroidism in neonates
may be associated with mild hypercalcemia in <40% of
children,(59) although it is rarely symptomatic and the mecha-
nisms remain unknown. Moreover, levothyroxine treatment in
children with congenital hypothyroidism(59) may also lead to an
increase in circulating levels of 1,25(OH)2D3 and hypercalciuria,
and hypercalcemia has been reported to only occur in neonates
with congenital hypothyroidism who were treated with
levothyroxine and vitamin D supplementation, although the
hypercalcemia was not correlated with circulating vitamin D
concentrations or metabolites of vitamin D.(60)
Renal tubular disorders
Distal renal tubular acidosis has been reported to be associated
with hypercalcemia.(61) In addition, Bartter syndrome type 1
(neonatal), which is characterized by metabolic alkalosis, renal
hypokalemia, and secondary hyperaldosteronism,(62) and is due
tomutations in the sodium-potassium-chloride co-transporter-2
gene (SLC12A1), has also been reported to be associated with
hypercalcemia, hypercalciuria, and nephrocalcinosis.(62–64) How-
ever, the hypercalcemia was associated with increased circulat-
ing PTH concentrations, which may be explained by an
inappropriate response to hypocalcemia secondary to hyper-
calciuria(63) and is consistent with marginally increased
circulating PTH concentrations that have been reported in
other, older children with Bartter syndrome.(64)
Inborn errors of metabolism
Inborn errors of metabolism that are reported to be associated
with hypercalcemia include hypophosphatasia (HPP), congen-
ital lactase deﬁciency (CLD), disaccharide intolerance, and blue
diaper syndrome. HPP is characterized by reduced bone
mineralization due to loss-of-function mutations in tissue-
nonspeciﬁc alkaline phosphatase (TNSALP), encoded by
the alkaline phosphatase liver/bone/kidney (ALPL) gene. HPP
is classiﬁed into six forms, and each is characterized by age of
onset and severity of symptoms, ranging from severe perinatal
(lethal), where respiratory distress from a hypoplastic chest is
the main cause of death, to milder odontohypophosphatasia,
where only dental manifestations are seen.(65) Patients present
perinatally or in childhood and >30% may have hypercalce-
mia.(66) The hypercalcemia is seen in the infantile form of HPP,
and may resolve spontaneously within the ﬁrst year of life,(67)
or following targeted asfotase alfa enzyme replacement
therapy.(68) However, hypercalcemia may occur in adults
with HPP who have been immobilized.(69) In CLD, the severely
reduced or absent activity of the gut enzyme lactase, leads
to an inability to breakdown dietary lactose, which results
in osmotic diarrhea, dehydration, and weight loss shortly
after feeding commences, and patients typically have
hypercalcemia with nephrocalcinosis. CLD, an autosomal
recessive disorder,(70–73) is caused by a mutation of the
lactase-phlorizin hydrolase gene, with a reported incidence of
1:60,000 newborns in Finland,(73) although it can occur in
other populations.(70–73) Hypercalcemia in CLD usually resolves
within weeks after starting a lactose-free diet, whereas
nephrocalcinosis may persist for years.(74) The hypercalcemia
in CLD may be secondary to, or exacerbated by, dehydration
and a metabolic acidosis, or be by a direct action of lactose on
the gut.(74) Hypercalcemia and nephrocalcinosis may also
complicate the presentation of sucrose-isomaltase deﬁ-
ciency,(75) and it is thought that there may be a similar
underlying mechanism to CLD. Blue diaper syndrome is due to
an abnormality of tryptophan metabolism that results in
diarrhea in association with excessive urinary excretion of
indole derivatives.(76) The characteristic “blue diaper” is caused
by the high levels of indican formed when high levels of
unabsorbed tryptophan in the intestine are metabolized by
bacteria.(76) The mechanisms causing hypercalcemia in blue
diaper syndrome, which is associated with hypercalciuria and
nephrocalcinosis, are not known. Hypercalcemia in the
absence of renal dysfunction may also be a rare complication
of primary oxalosis(77) and has also been reported in IMAGe
syndrome (characterized by intrauterine growth restriction,
metaphyseal dysplasia, adrenal hypoplasia congenita, and
genital anomalies).(78)
Immobilization
Immobilization hypercalcemia may occur in 10% to 23% of
children with spinal cord injuries, in association with suppressed
plasma PTH concentrations, within 4 to 8 weeks of the injury,(79)
and be preceded by hypercalciuria, which may develop within
the ﬁrst week and continue for up to 18 months.(79) Immobiliza-
tion hypercalcemia also occurs in some children after single-
limb fractures.(80) The hypercalcemia is more common in
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adolescents and males, possibly because of increased bone
turnover associated with rapid growth, and a higher bone mass,
respectively.(79) The mechanism is not understood but is
thought to result from increased osteoclastic activity and
reduced osteoblastic activity due to a lack of mechanical
stimulation.(79)
Congenital syndromes and diseases
Hypercalcemia is more likely to be genetic in children than in
adults, and may occur as part of congenital syndromes that are
associated with dysmorphism and/or skeletal abnormalities.
These disorders, which include Williams syndrome, Jansen’s
disease, and Down syndrome, are often detected early in life.
However, in some cases dysmorphia may be subtle or missed,
and therefore the diagnoses should not necessarily be ruled out
on the basis of age alone.
Williams syndrome
Williams syndrome affects approximately 1 in 7,500 to 10,000
individuals(81) and is characterized by elﬁn-like facies, learning
disabilities, supravalvular aortic stenosis, nephrocalcinosis,
urinary tract abnormalities, and endocrinopathies, including
hypercalcemia, which affects 5% to 50% of patients.(81–83) It
usually occurs sporadically, but may be inherited in an
autosomal-dominant manner.(84) The mechanisms causing
hypercalcemia, which may resolve spontaneously within days
to weeks,(83) remain unknown, but abnormal 1,25(OH)2D3
metabolism and decreased calcitonin production have been
implicated,(81,83,85) although no abnormality has been consis-
tently demonstrated. Hemizygosity due to a microdeletion of
chromosome 7q11.23 involving the ELASTIN and LIM-KINASE
genes, which may explain the respective cardiovascular and
neurologic features, have been reported in Williams syndrome.
However, the calcitonin receptor gene, located on chromosome
7q21 and close to the region deleted in Williams syndrome, was
not involved in the deletion in four patients, indicating that it is
unlikely to be implicated in the hypercalcemia of such children.
Another, as-yet-uncharacterized gene that is within this
contiguously deleted region is likely to be involved to explain
the abnormalities of calcium metabolism.
Jansen’s disease
Jansen’s metaphyseal chondrodysplasia is an autosomal-
dominant disease characterized by short-limbed dwarﬁsm in
association with severe hypercalcemia and hypercalciuria,
despite normal or undetectable PTH and PTHrP concentra-
tions. These abnormalities are associated with heterozygous
mutations of the PTH-PTHrP receptor, causing constitutive
ligand-independent activation.(86)
Down syndrome
Down syndrome, which is due to trisomy 21, is one of the most
frequent genetic causes of dysmorphism, and occurs in 1 in 690
live births.(87) Down syndrome has been reported in association
with hypercalcemia and nephrocalcinosis in six patients.(88) The
mechanisms causing the hypercalcemia are unknown, although
the hypercalcemia does appear to respond to dietary calcium
restriction suggesting increased intestinal absorption as a
possible etiology.(88)
Acquired causes of neonatal hypercalcemia
Nutritional
Enriched formula and/or phosphate depletion can cause
hypercalcemia in preterm newborns(89) and, less frequently, in
newborns born at term.(90) Phosphate depletion may suppress
secretion of FGF23, alleviating the inhibitory effect of FGF23 on
1,25(OH)2D3 production (Fig. 1), causing an increase in 1,25
(OH)2D3 levels resulting in hypercalcemia. The data on plasma
PTH concentrations from such babies is scant and it has been
suggested that as the hypercalcemia is associated with
hypophosphatemia and increased plasma 1,25(OH)2D3 concen-
trations, then the plasma PTH is likely to be low.(90) The
hypercalcemia in these very low birth weight babies fed breast
milk, which has a relatively high calcium to phosphate content,
can be ameliorated by early administration of phosphate
supplements.(89)
PTH-Dependent Hypercalcemia
PTH-dependent hypercalcemia is usually caused by parathyroid
tumors, which may give rise to PHPT or tertiary hyperparathy-
roidism (Table 1, Fig. 2). PHPT usually occurs as an isolated
nonsyndromic nonhereditary endocrinopathy and less com-
monly, as part of inherited complex syndromic disorders such as
multiple endocrine neoplasia (MEN) and hyperparathyroid jaw-
tumor syndrome (HPT-JT).(91) Tertiary hyperparathyroidism
usually arises in association with chronic renal failure, and
may also occur in the treatment of children with hypophos-
phatemic rickets.(92)
The main non–parathyroid tumor–related cause of PTH-
dependent hypercalcemia in children is gestational maternal
hypocalcemia (Table 1). This acquired cause of hypercalcemia
may be apparent from the clinical history and preliminary
investigations, whereas the causes associated with parathyroid
tumors, which include genetic abnormalities, may be more
challenging, and are reviewed further in the next section.
Genetic causes of hypercalcemia
PHPT may occur as a hereditary familial disorder or
sporadically, ie, as nonfamilial disease(93–95); however, distin-
guishing between sporadic and nonfamilial forms may
sometimes be difﬁcult. Sporadic PHPT may be the result of
a de novo germline mutation in the patient or due to an
inherited mutation with an absent family history; eg, if family
members have not been investigated or have died before
developing symptoms.(91) Both de novo and inherited
mutations resulting in PHPT will lead to an increased risk of
hereditary PHPT in the children of the patient.(93–96) Studies of
patients with both syndromic and nonsyndromic forms of
PHPT have shown that >10% will harbor a germline mutation
in one of 12 genes (Table 3).(55,93,94,97,98) The nonsyndromic
forms, which include FHH, NSHPT, and familial isolated primary
hyperparathyroidism (FIHP), are likely to be more frequent
than the syndromic disorders of MEN and HPT-JT.
Syndromic PHPT
MEN
MEN is an autosomal dominant disorder in which patients
develop two or more endocrine tumors. Four types of MEN
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(MEN1 to MEN4) are recognized with each associated with a
distinct set of endocrine tumors; however, parathyroid tumors
occur in all of the MEN syndromes. Thus, in MEN1 patients,
parathyroid tumors occur in 95% of patients in association
with pancreatic islet cell tumors (40% of patients), anterior
pituitary tumors (30% of patients), and adrenocortical
tumors (40% of patients).(96) In MEN1, parathyroid tumors
causing hypercalcemia are the ﬁrst manifestation of the
disease in 90% of patients, and parathyroid tumors may
develop as early as 8 years of age, although only 17% of cases
below 21 years of age will be symptomatic with urolithiasis,
fatigue, and bone pain, with the youngest symptomatic case
being aged 8 years with urolithiasis.(99) In MEN1, hyperpara-
thyroidism is typically a multigland disease affecting all four
parathyroid glands and patients who undergo subtotal
parathyroidectomy usually develop recurrent hypercalcemia
within a decade.(100,101) In MEN2, parathyroid tumors occur in
20% of patients, in association with medullary thyroid
carcinoma (MTC) (99% of patients) and pheochromocytomas
(50% of patients).(96,101) In MEN3, MTC and pheochromocy-
tomas are also common, but parathyroid tumors are rarely
seen; instead patients have other features such as a Marfanoid
habitus, mucosal neuromas, medullated corneal nerve ﬁbers,
and intestinal autonomic ganglion dysfunction leading to
multiple diverticula and megacolon. Only a few patients with
MEN4 have been described; all have parathyroid tumors in
association with other tumors affecting the adrenals, pituitary,
and gonads.(102) MEN1 is caused by a mutation in the tumor
suppressor MEN1 gene encoding menin; MEN2 and MEN3 are
caused by mutations in the proto-oncogene RET, encoding a
tyrosine kinase receptor; and MEN4 is caused by mutations of
CDNK1B, encoding p27.(96,101)
HPT-JT
HPT-JT syndrome, an autosomal dominant disorder, is charac-
terized by the development of multiple parathyroid tumors,
which may be carcinomas, and ﬁbro-osseous tumors of the
maxilla and mandible.(94) Some families also have increased risk
of developing renal tumors and affected women have greater
risk of developing uterine tumors.(94) However, in some families
the affected individuals may have developed only parathyroid
tumors without other tumors or jaw tumors, and this may cause
confusion with other hereditary hypercalcemic disorders such as
MEN1, FHH, and FIHP.(93) HPT-JT is due to mutations of the cell
division cycle 73 (CDC73) gene, which is a tumor suppressor
encoding paraﬁbromin that is involved in transcriptional and
posttranscriptional pathways.(94) Parathyroid tumors with hy-
percalcemia occur in>70%of individuals with CDC73mutations,
with the onset being typically in late adolescence or early
adulthood.(103–106) The youngest patient reported with hyper-
calcemia is 7 years old,(103) and the youngest patient reported
with parathyroid carcinoma is 20 years old.(107) Germline
pathogenic CDC73 mutations have also been reported in
patients with apparently sporadic: parathyroid carcinoma;
parathyroid adenoma; or ossifying ﬁbromas of the jaw.(108)
Due to the potential for early onset of tumors, biochemical
surveillance for PHPT, starting from age 5 to 10 years, is
recommended in individuals known to be at risk.(103)
Nonsyndromic PHPT
FHH
FHH is characterized by lifelong elevations of serum calcium
concentrations, elevated or inappropriately normal plasma PTH
concentrations, and lowurinary calcium excretion resulting from
PTH-independent reduced calcium excretion in the kidneys.(109)
The hypercalcemia of FHH is considered to be primarily due to
inappropriate conservation of calcium in the kidney rather than
being driven by an inappropriate PTH concentration.(109) The
mean calcium-to-creatinine clearance ratio (CCCR) (measured in
either molar units or mass units) is typically <0.01 in FHH.
However, more than 20% FHH patients have a CCCR >0.01, and
such patients are at risk of being misdiagnosed with
PHPT.(110–112) In contrast to PHPT, the hypercalcemia in FHH is
generally benign and is not corrected by parathyroidectomy;
therefore, distinguishing between PHPT and FHH is important to
avoid unnecessary surgery in FHH patients.
FHH is an autosomal-dominant, genetically heterogeneous
disorder with three clinically indistinguishable variants (FHH1 to
FHH3).(111,113) FHH1 comprises65% of FHH patients and is due
to loss-of-function mutations of CaSR, a G-protein-coupled
receptor (GPCR). FHH2 comprises <5% of all FHH patients and
Table 3. Genetic Disorders Associated With Primary Hyperparathyroidism
Disordera Chromosomal location Gene
FHH1 3q21.1 CASR
FHH2 19p13 GNA11
FHH3 19q13.2–q13.3 AP2S1
NSHPT 3q21.1 CASR
nsPHPT 11p15.3 –p15.1, 6p21.2, 9p21, 1p32, 6p24.2 PTH,b CDKN1A, CDKN2B, CDKN2C, GCM2c
FIHP 11q13, 1q31.2, 3q21.1, 6p24.2 MEN1, CDC73, CASR, GCM2c
MEN1 11q13 MEN1
MEN2/MEN3 10q11.2 RET
MEN4 12p13 CDKN1B
HPT-JT 1q31.2 CDC73
FHH1/FHH2/FHH3¼ familial hypocalciuric hypercalcemia types 1, 2, and 3; NSHPT¼neonatal severe primary hyperparathyroidism; nsPHPT¼non-
syndromic primary hyperparathyroidism; FIHP¼ familial isolated hyperparathyroidism; MEN1/MEN2/MEN3/MEN4¼multiple endocrine neoplasia types
1, 2, 3, and 4; HPT-JT¼hyperparathyroid jaw-tumor syndrome.
aInheritance of all disorders is autosomal dominant, but NSHPT can be recessive.
bA nonsense PTH mutation has been reported in one patient.
cActivating mutations of GCM2.
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is due to loss-of-function mutations of GNA11, which encodes G-
protein subunita-11 (Ga11).
(111) FHH3may occur in20% of FHH
patients without CaSR mutations(9) and is due to loss-of-function
mutations of the adaptor-related protein complex 2, sigma 1
subunit (AP2S1) gene. The AP2S1 gene encodes the adaptor-
protein 2 sigma (AP2s) subunit that forms a heterotetramer with
other subunits, and plays a central role in clathrin-mediated
endocytosis of plasma membrane constituents such as GPCRs.(9)
As FHH is usually asymptomatic, the age of diagnosis will be
variable, with individuals with concurrent medical problems or
hypercalcemic symptoms being detected earlier. The youngest
age of diagnosis of FHH1 is in a 4.5-month-old Greek infant who
had a urinary tract infection with incidental hypercalcemia.(114)
The youngest age for diagnosis of FHH3 is in a Japanese infant
who at age 49 days presented with poor weight gain and had an
AP2S1 mutation.(115) FHH3 children are more likely than FHH1
children to be symptomatic, and to have additional phenotypic
features, and thus may present earlier.(116) For example, four
FHH3 children, aged<1 to 11 years, have been reported to have
learning difﬁculties (LDs); one aged 14 years had LD, pancreatitis,
and short stature (SS); and one aged 15 years had LD, an atrial
septal defect, and SS.(116)
NSHPT
NSHPT usually presents at birth with marked hypercalcemia,
hypotonia, respiratory distress, and bone demineralization, and
is usually fatal by 3 months if untreated. Bone demineralization
occurs due to osteoclast overactivity and can result in bone
deformities and fractures presenting at birth. Respiratory
difﬁculties may arise from rib cage involvement. Most cases
are associated with homozygous or compound heterozygous
loss-of-function CaSRmutations(117) and somemay occur in FHH
families, either through inheriting two mutated copies of the
CASR gene as in consanguineous families, or one copy together
with a de novo CASR mutation. Urgent parathyroidectomy is
lifesaving and the treatment of choice, but pamidronate or
cinacalcet have been used for treatment while awaiting
surgery.(118) Cinacalcet is a positive allosteric modulator of the
CaSR and will ameliorate signaling disturbances associated with
most loss-of-function CaSR mutations; however, if both CASR
alleles have mutations whereby the CaSR is not expressed, eg,
with a homozygous deletion in exon 5 (c.1392_1404del13), then
cinacalcet will be ineffective.(119) Some centers distinguish
between NSHPT and neonatal hyperparathyroidism (NHPT) on
the basis of homozygous and heterozygous CaSR mutations,
respectively. NHPT may be associated with less marked and
symptomatically transient hypercalcemia than NSHPT, with
some patients developing symptomless FHH, and therefore not
requiring parathyroid surgery.(120) This highlights the value of
CASR mutational analysis in distinguishing NSHPT from NHPT.
FIHP
FIHP is characterized by hereditary PHPT occurring without the
association of other tumors and has been described in >100
families.(91,93) The diagnosis of FIHP is based on excluding other
hereditary disorders associated with PHPT, such as MEN1, MEN2,
MEN4, HPT-JT, and FHH, and by screening for mutations in
known causative genes, such asMEN1, RET, CDKN1B, CDC73, and
CASR, respectively.(91) In the majority of these families the
genetic etiology of FIHP remains unknown.(121,122) However,
patients with activatingmutations of glial cellsmissing 2 (GCM2),
a parathyroid-speciﬁc transcription factor, have been re-
ported,(123) as well as one PHPT patient who had a nonsense
mutation of the PTH gene.(124) Approximately 10% of patients
presenting under the age of 45 years with sporadic PHPT will
have a de novo germline MEN1, CDC73, GCM2, or CASR
mutation,(93–95,125,126) and this has implications for their future
management, to ensure appropriate screening for complica-
tions associated with the speciﬁc syndrome, and for screening
ﬁrst-degree relatives. The ﬁnding of a mutation in MEN1, RET,
CDC73, or CDKN1B in an apparent FIHP kindred would lead to a
revised diagnosis of one of the associated syndromes with
incomplete penetrance(93) and, in some families, FIHP may
represent an incomplete manifestation of a syndromic form of
PHPT caused by an as-yet-undiscovered mutation.(93,127,128)
Some patients diagnosed as having FIHP have later been
reported to develop features of MEN1(93–97,127) and, in addition,
some FIHP kindreds have associated MEN1 mutations and may
represent an allelic variant of MEN1.(127)
FIHP may be distinguished from MEN1, FHH, and HPT-JT
through clinical, histological, and genetic ﬁndings. Over 90% of
MEN1 and HPT-JT patients develop hypercalcemia as their ﬁrst
manifestation of the disease, and distinguishing between MEN1
and HPT-JT patients at this early stage from FIHP patients can be
difﬁcult.(91,93,98) It is important to distinguish FIHP from HPT-JT
because HPT-JT patients are at higher risk for developing
parathyroid carcinomas.(129–132) The presence of ossifying ﬁbro-
masof the jaw is an importantdistinguishing featureofHPT-JTand
the identiﬁcation of renal, pancreatic, thyroid, and testicular
abnormalities may also help to identify HPT-JT patients. The jaw
tumors in HPT-JT differ from the brown tumors observed in some
PHPT patients and do not resolve after parathyroidectomy.(133)
Similarly, theoccurrenceof pancreatic, pituitary, or adrenal tumors
in the patient or family will suggest a diagnosis of MEN1 rather
than FIHP. FIHP may be distinguished from FHH on the basis of
plasma and urinary calcium ﬁndings. In FHH, serum calcium levels
are elevated from the neonatal period, whereas in FIHP,
hypercalcemia rarely occurs until after the ﬁrst decade.(98,127)
FIHP patients are likely to have associated hypercalciuria, unlike
FHH patients who usually have a CCCR<0.01.(116) However, there
are considerable clinical overlaps between these disorders, and
genetic testing is advisable for making the correct diagnosis.
Genetic testing in patients with syndromic and nonsyndromic
forms of PHPT
Genetic testing for mutations in PHPT patients is worthwhile
because>10%of patientswith PHPTwill have amutation in one of
13 genes (Table 3) and therefore beneﬁt from an accurate
diagnosis.(91) Thus, genetic testingmayprovide conﬁrmationof the
clinical diagnosis (ie, syndromic or nonsyndromic PHPT) and allow
appropriate screening for associated tumors to be undertaken,
with implementation of appropriate treatment, eg, early parathy-
roidectomy for HPT-JT patients who are at increased risk of
developing parathyroid carcinomas; appropriate parathyroid
surgery in MEN1 patients who generally have multigland disease
requiring open neck exploration; and avoidance of unnecessary
parathyroidectomies in FHH patients.(91) Asymptomatic mutation
carriers should receive screening for associated tumors to facilitate
appropriate treatment, and the50%of familymemberswhodonot
harbor the germline mutation can be reassured and alleviated of
the anxiety of developing the condition,(93–95) thereby reducing
costs to the individuals, and also to the health services in avoiding
unnecessary biochemical and radiological investigations.(93–95,98)
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Indications for genetic testing in PHPTpatients include: (i) young
age of presentation, ie,<45 years of age; (ii) multigland disease; (iii)
parathyroid carcinoma or atypical parathyroid adenomas (eg, with
ﬁbrous bands or cysts); (iv) being a ﬁrst-degree relative of a known
mutation carrier; and (v) beingan index casewith twoormoreMEN
syndrome–associated tumors.(93–95,98,126,134) Patients should be
offered genetic counseling prior to testing, and genetic testing
should use non-tumor cells (eg, DNA obtained from leukocytes,
salivary cells, skin cells, or hair follicles), because DNA from
parathyroid tumors may contain multiple mutations in addition to
the germline mutation and therefore are not clinically useful.(91)
Individuals with PHPT identiﬁed to have a germline mutation
should enter into an appropriate screening program; eg, for MEN-
associated and HPT-JT–associated tumors.(93,94) If no genetic
abnormalities are found within the 13 genes (Table 3), and clinical
manifestations of hereditary or syndromic forms of PHPT are
absent, then the likelihood of a MEN syndrome, HPT-JT or FHH is
low (ie, <5%).(93–95,98) The ﬁrst-degree relatives of PHPT patients,
including children, with a germline mutation should be offered
genetic counseling and appropriate gene testing, and any affected
individuals subsequently identiﬁed should also enter into an
appropriate screening program, even if asymptomatic.(93–95,134)
First-degree relatives who have not inherited the causative
mutation require no further follow-up and can be reassured.(93,94)
Patients who present with PHPT at a later age, ie, >45 years,
and who have an underlying syndromic etiology for their PHPT,
aremore likely to havemanifested other associated features that
may be revealed during clinical evaluation. A detailed family
history for PHPT (ie, FIHP), MEN syndrome, HPT-JT, or FHH should
be undertaken, and gene testing should then be offered to
determine the etiology of the PHPT.(93–95,110,124,134) However, up
to 5% of patients >45 years of age with sporadic PHPT due to a
solitary parathyroid adenoma may have a germline mutation
involving CDKN1A, CDKN2B, or CDKN2C,(91) and this may have
implications for their children. Such ﬁrst-degree relatives of a
patient with a mutation in CDKN1A, CDKN2B, or CDKN2Cwho are
also found to be mutation carriers should then have periodic
screening to detect the onset of hypercalcemia in order to
facilitate appropriate earlier treatment aimed at preventing the
skeletal and renal complications of PHPT.(93,95,97,98)
Acquired causes of neonatal hypercalcemia
Neonatal hyperparathyroidism
Neonatal hyperparathyroidismmaybe an adaptation tomaternal
hypocalcemia due to hypoparathyroidism, vitamin D deﬁciency,
pseudohypoparathyroidism, or renal tubular acidosis,(4) although
in the latter, PTH is often high with normal calcium. Maternal
hypervitaminosis D does not usually affect the neonate because
1,25(OH)2D3 is inactivated by the placenta, so excessivematernal
1,25(OH)2D3 consumption should not cause hypercalcemia in the
newborn. However, there have been case reports of excessive
maternal intake of 1,25(OH)2D3 and 25(OH)D3 causing hypercal-
cemia in the neonate.(135,136)
Extracorporeal membrane oxygenation
Extracorporeal membrane oxygenation (ECMO) is a technique
used in pediatric resuscitation as a way of providing tissue
oxygenation in cases of refractory hypoxemia to allow time for
treatment of the underlying cause of the disorder to take
effect. It is associated with metabolic disturbances including
hypercalcemia,(137–139) although the mechanisms for this are
not known, but may be related to increased circulating PTH
concentrations.(138)
Management of Hypercalcemia
The management of hypercalcemia involves establishing the
underlying diagnosis in parallel with lowering serum calcium
levels. Medications that may cause or exacerbate the hypercal-
cemia, such as calcium and vitamin D preparations, should be
stopped. Symptomatic hypercalcemia may require ﬂuid admin-
istration to rectify intravascular volume contraction caused by
hypercalcemia-induced nephrogenic diabetes insipidus.(140)
Normal (0.9%) saline given intravenously is effective at
rehydrating the patient, thereby diluting serum calcium
concentrations.(5) Moreover, normal saline lowers serum calcium
concentrations by promoting urinary calcium excretion from the
proximal renal tubule and loop of Henle.(140) Loop diuretics such
as furosemide can also enhance urinary calcium excretion,(140)
but should be used cautiously because they may exacerbate the
intravascular volume contraction and lead to renal im-
pairment.(4) Subcutaneous calcitonin is an effective antiresorp-
tive agent for symptomatic hypercalcemia; however, its effects
are short-lived due to tachyphylaxis.(4) The use of i.v. bi-
sphosphonates leads to a more sustained reduction in serum
calcium concentrations, and pamidronate (0.5 to 1.0mg/kg) is
used most commonly in children.(140) Patients should be
adequately hydrated prior to receiving i.v. bisphosphonates in
order to minimize the potential risk of nephrotoxicity, which has
been widely reported in adults.(141) Glucocorticoids such as
prednisolone are effective at rectifying hypercalcemia caused by
granulomatous disorders, although long-term use may increase
skeletal fragility and impair linear growth.(4,140) Cinacalcet, which
is a CaSR-positive allosteric modulator, has been successfully
used to manage life-threatening hypercalcemia in some NSHPT
probands.(142) However, the effectiveness of cinacalcet for
NSHPT will depend on the underlying CaSR mutation, and
patients harboring biallelic truncating CaSR mutations will be
unlikely to respond to this calcimimetic agent.(143) Parathyroid-
ectomy remains the treatment of choice for children with
primary hyperparathyroidism or NSHPT because it represents a
curative procedure for these disorders.(144) Hypocalcemia due to
hungry bone syndrome or postsurgical hypoparathyroidism
represents the most common complication of parathyroidec-
tomy, and close monitoring of serum calcium concentrations is
required following surgery.(140,144)
Conclusions
Themajority of causes of hypercalcemia in children are similar to
those in adults, but occur at different frequencies across the age
spectrum from birth to maturity. Hypercalcemia has a broad
differential diagnosis (Table 1), and comprehensive clinical
assessment followed by stepwise use of investigations is
necessary to elucidate the underlying cause (Fig. 2). Determining
the etiology of hypercalcemia is critical for successful treatment
and for ensuring the child’s growth and development.
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